Document is current
Any future updates will be listed below
-
Authors
Lemech, Charlotte
Dredge, Keith
Bampton, Darryn
Hammond, Edward https://orcid.org/0000-0001-7405-8684
Clouston, Andrew
Waterhouse, Nigel J
Stanley, Amanda C
Leveque-El Mouttie, Lucie
Chojnowski, Grace M
Haydon, Andrew
Pavlakis, Nick
Burge, Matthew
Brown, Michael P https://orcid.org/0000-0002-5796-1932
Goldstein, David
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct05061017 at ClinicalTrials.govnct05061017 at ClinicalTrials.govDocuments that mention this clinical trial
721 Pixatimod (P) in combination with nivolumab (N) +/- low-dose cyclophosphamide (Cy) in advanced cancers: a phase IIA basket trial
https://doi.org/10.1136/jitc-2022-sitc2022.0721
Phase Ib open-label, multicenter study of pixatimod, an activator of TLR9, in combination with nivolumab in subjects with microsatellite-stable metastatic colorectal cancer, metastatic pancreatic ductal adenocarcinoma and other solid tumors
https://doi.org/10.1136/jitc-2022-006136
Documents that mention this clinical trial
721 Pixatimod (P) in combination with nivolumab (N) +/- low-dose cyclophosphamide (Cy) in advanced cancers: a phase IIA basket trial
https://doi.org/10.1136/jitc-2022-sitc2022.0721
Phase Ib open-label, multicenter study of pixatimod, an activator of TLR9, in combination with nivolumab in subjects with microsatellite-stable metastatic colorectal cancer, metastatic pancreatic ductal adenocarcinoma and other solid tumors
https://doi.org/10.1136/jitc-2022-006136
-
Funding
Funding for this research was provided by:
Bristol Myers Squibb, Australia (N/A)
Zucero Therapeutics Ltd (N/A)
- License Information
